A lentiviral platform for in vivo T-cell engineering, wherein viral particles were coated with anti-CD3 scFv’s to allow for T-cell targeting, showed compelling proof of concept data with a CD19 CAR-T construct in both successful biodistribution within canine models and anti-tumor activity in Nalm-6 tumor bearing mice [111]. The gene discussed is CD19; the disease is neoplasm.